m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00433
 [1], [2], [3]
m6A modification TP53 TP53 YTHDF2 : m6A sites Indirect Enhancement RNA modification MIR125A MIR125A METTL1 Methylation : modification sites
m6A Modification:
m6A Regulator YTH domain-containing family protein 2 (YTHDF2) READER
 Regulator Info 
m6A Target Cellular tumor antigen p53 (TP53/p53)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> N7-methylguanosine (m7G)
Epigenetic Regulator Methyltransferase-like protein 1 (METTL1) WRITER View Details
Regulated Target MicroRNA 125a (MIR125A) View Details
Crosstalk Relationship m7G  →  m6A Enhancement
Crosstalk Mechanism RNA modification indirectly impacts m6A modification through downstream signaling pathways
Crosstalk Summary METTL1 interacts with MicroRNA 125a (MIR125A), increasing it's m7G level and promoting its physical interaction with Cellular tumor antigen p53 (TP53/p53), which was regulated by YTHDF2-mediated m6A modification.
In-vitro Model
 OCM-1 Amelanotic melanoma Homo sapiens CVCL_6934
CRMM-1 Conjunctival melanoma Homo sapiens CVCL_M593
A-549 Lung adenocarcinoma Homo sapiens CVCL_0023
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Cellular tumor antigen p53 (TP53/p53) 27 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Contusugene ladenovec Phase 3 [4]
Synonyms
Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR
    Click to Show/Hide
MOA Modulator
External Link
TTD: D04FYL
 Compound Name QPI-1002 Phase 3 [5]
MOA Modulator
External Link
TTD: D0D5ZU
 Compound Name Thymoquinone Phase 2/3 [6]
Synonyms
490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10281
TTD: DY4OZ6
 Compound Name SGT-53 Phase 2 [7]
Synonyms
P53 gene stimulator (solid tumor), Synergene Therapeutics
    Click to Show/Hide
MOA Stimulator
External Link
TTD: D02EOH
 Compound Name APR-246 Phase 2 [8]
Synonyms
Eprenetapopt
    Click to Show/Hide
MOA Stimulator
External Link
CID: 52918385
TTD: D03XTY
DrugBank: DB11684
 Compound Name Ad-p53 Phase 2 [9]
Synonyms
P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0CO9B
 Compound Name Kevetrin Phase 2 [10]
MOA Stimulator
External Link
CID: 437740
TTD: D0K7DV
DrugBank: DB13010
 Compound Name INGN-225 Phase 2 [11]
Synonyms
Cancer vaccine (p53), Introgen
    Click to Show/Hide
External Link
TTD: D0V2SP
 Compound Name ALT-801 Phase 2 [12]
Synonyms
ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor
    Click to Show/Hide
MOA Immunomodulator (Immunostimulant)
External Link
TTD: D0V5JH
 Compound Name APG-115 Phase 2 [10]
Synonyms
15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 91972012
TTD: D04SXL
 Compound Name ISA-P53-01 Phase 1/2 [13]
Synonyms
P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals
    Click to Show/Hide
External Link
TTD: D0KK4N
 Compound Name SAR-405838 Phase 1 [14]
Synonyms
AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis
    Click to Show/Hide
MOA Modulator
External Link
CID: 53476877
TTD: D03YSQ
DrugBank: DB12541
 Compound Name Dendritic cell vaccine Phase 1 [15]
Synonyms
Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute
    Click to Show/Hide
External Link
TTD: D05CPS
 Compound Name ONYX-015 Phase 1 [16]
Synonyms
Dl1520; E1B-deleted adenovirus (cancer), ONYX
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0G7YS
 Compound Name COTI-2 Phase 1 [10]
Synonyms
UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide
    Click to Show/Hide
MOA Modulator
External Link
CID: 91810660
TTD: D0G8CU
 Compound Name CGM097 Phase 1 [5]
MOA Modulator
External Link
CID: 53240420
TTD: D0Q7AG
 Compound Name HDM201 Phase 1 [17]
MOA Inhibitor
External Link
CID: 71678098
TTD: D01KTG
 Compound Name INGN-234 Discontinued in Phase 2 [18]
Synonyms
P53 tumor suppressor (topical formulation), Introgen
    Click to Show/Hide
MOA Suppressor
External Link
TTD: D05AHK
 Compound Name Pifithrin-alpha Terminated [19]
Synonyms
P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9929138
TTD: D02NYK
 Compound Name TAR-1 Terminated [20]
Synonyms
P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions
    Click to Show/Hide
External Link
TTD: D0LG1K
 Compound Name 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Investigative [21]
Synonyms
PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 4722579
TTD: D08PLU
DrugBank: DB08363
 Compound Name NUTLIN-3 Investigative [22]
Synonyms
548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 216345
TTD: D01QKK
 Compound Name NU-8231 Investigative [23]
Synonyms
SCHEMBL2454464; CHEMBL360944
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11648438
TTD: D0F1SN
 Compound Name OPI-1002 Phase 2 [24]
External Link
TTD: D02CKH
 Compound Name Cenersen Phase 2 [24]
External Link
CID: 56841947
TTD: D0K4VW
 Compound Name AHL Investigative [24]
Synonyms
AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark
    Click to Show/Hide
External Link
TTD: D0T8EL
 Compound Name PC14586 Phase 1/2 [24]
External Link
TTD: D53CGK
References
Ref 1 Histone lactylation drives oncogenesis by facilitating m(6)A reader protein YTHDF2 expression in ocular melanoma. Genome Biol. 2021 Mar 16;22(1):85. doi: 10.1186/s13059-021-02308-z.
Ref 2 METTL1 Promotes let-7 MicroRNA Processing via m7G Methylation. Mol Cell. 2019 Jun 20;74(6):1278-1290.e9. doi: 10.1016/j.molcel.2019.03.040. Epub 2019 Apr 25.
Ref 3 LncRNA miR143HG Up-Regulates p53 In Endometrial Carcinoma By Sponging miR-125a. Cancer Manag Res. 2019 Dec 2;11:10117-10123. doi: 10.2147/CMAR.S222215. eCollection 2019.
Ref 4 A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther. 2009 Feb;11(1):54-61.
Ref 5 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 6 Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. doi: 10.1016/j.drudis.2020.04.023. Epub 2020 May 7.
Ref 7 Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr;20(4):222-8. doi: 10.1038/cgt.2013.9. Epub 2013 Mar 8.
Ref 8 APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4(10):e881. doi: 10.1038/cddis.2013.417.
Ref 9 Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 2003 Mar;10(3):224-38. doi: 10.1038/sj.cgt.7700562.
Ref 10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 11 INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91. doi: 10.1517/14712598.2010.484801.
Ref 12 Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75. doi: 10.1158/1078-0432.CCR-11-1817. Epub 2011 Oct 12.
Ref 13 WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
Ref 14 SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014 Oct 15;74(20):5855-65. doi: 10.1158/0008-5472.CAN-14-0799. Epub 2014 Aug 21.
Ref 15 Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004 Jul;53(7):633-41. doi: 10.1007/s00262-003-0493-5. Epub 2004 Feb 25.
Ref 16 Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004 Dec;6(6):611-23. doi: 10.1016/j.ccr.2004.11.012.
Ref 17 National Cancer Institute Drug Dictionary (drug id 761551).
Ref 18 Prevent Oral Cancer With Mouthwash. Introgen Therapeutics.
Ref 19 An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines. Mol Cancer Ther. 2005 Sep;4(9):1369-77. doi: 10.1158/1535-7163.MCT-04-0341.
Ref 20 Regulation of host gene expression by HIV-1 TAR microRNAs. Retrovirology. 2013; 10: 86.
Ref 21 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.
Ref 22 Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. J Med Chem. 2009 Nov 26;52(22):7044-53. doi: 10.1021/jm900681h.
Ref 23 Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem. 2006 Oct 19;49(21):6209-21. doi: 10.1021/jm0601194.
Ref 24 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.